The Committee for Medicinal Products for Human Use (CHMP) concluded that Jalra’ s benefits in the treatment of type 2 diabetes mellitus are greater than its risks when used as dual oral therapy in combination with metformin, a sulphonylurea or a thiazolidinedione.